https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49803 38 years (1.34; 1.04–1.73); those with disease duration > 7 years (1.33; 1.01–1.74); those with EDSS score < 6 (1.21; 1.01–1.46) and ≥ 6 (1.93; 1.11–3.34); and patients with no new MRI lesion (1.73; 1.19–2.51). Conclusions: Overall, in women, younger patients, those with shorter disease durations, and patients with pre-treatment relapses, natalizumab was associated with a lower frequency of multiple sclerosis relapses than fingolimod. It was also associated with an increased chance of recovery from disability among most patients, particularly women and those with no recent MRI activity.]]> Wed 31 May 2023 15:59:42 AEST ]]> Risk of secondary progressive multiple sclerosis: a longitudinal study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38068 p <0.001), longer disease duration (HR=1.01, p=0.038), a higher Expanded Disability Status Scale score (HR=1.30, p<0.001), more rapid disability trajectory (HR=2.82, p<0.001) and greater number of relapses in the previous year (HR=1.07, p=0.010) were independently associated with an increased risk of secondary progressive multiple sclerosis. Improving disability (HR=0.62, p=0.039) and disease-modifying therapy exposure (HR=0.71, p=0.007) were associated with a lower risk. Recent cerebral magnetic resonance imaging activity, evidence of spinal cord lesions and oligoclonal bands in the cerebrospinal fluid were not associated with the risk of conversion. Conclusion:Risk of secondary progressive multiple sclerosis increases with age, duration of illness and worsening disability and decreases with improving disability. Therapy may delay the onset of secondary progression.]]> Wed 24 May 2023 12:22:34 AEST ]]> Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33927 Wed 23 Jan 2019 15:30:44 AEDT ]]> Defining reliable disability outcomes in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22648 Wed 22 May 2019 14:50:34 AEST ]]> Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13691 Wed 11 Apr 2018 17:01:07 AEST ]]> Geographical variations in sex ratio trends over time in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13697 Wed 11 Apr 2018 16:44:40 AEST ]]> Predictors of disability worsening in clinically isolated syndrome https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28397 Wed 11 Apr 2018 15:14:13 AEST ]]> Comparative efficacy of switching to natalizumab in active multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25641 Wed 11 Apr 2018 15:12:45 AEST ]]> Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13693 Wed 11 Apr 2018 14:32:54 AEST ]]> Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28923 Wed 11 Apr 2018 10:33:05 AEST ]]> Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45667 Wed 02 Nov 2022 15:59:08 AEDT ]]> Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34542 Tue 26 Mar 2019 15:11:01 AEDT ]]> Delay from treatment start to full effect of immunotherapies for multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39111 Tue 21 Mar 2023 17:45:24 AEDT ]]> Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27384 Tue 13 Oct 2020 19:16:32 AEDT ]]> Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27446 Tue 13 Oct 2020 19:11:18 AEDT ]]> Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49895 Tue 13 Jun 2023 15:49:48 AEST ]]> Confirmed disability progression as a marker of permanent disability in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52212 88% likely to be sustained (events with score ˃1.5). Conclusions: Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.]]> Thu 05 Oct 2023 10:22:58 AEDT ]]> Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33303 Thu 04 Oct 2018 16:49:43 AEST ]]> Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36736 Thu 02 Jul 2020 16:31:45 AEST ]]> Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41240 Sat 30 Jul 2022 12:19:30 AEST ]]> Fingolimod after natalizumab and the risk of short-term relapse https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20798 Sat 24 Mar 2018 08:05:59 AEDT ]]> Predictors and dynamics of postpartum relapses in women with multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17471 Sat 24 Mar 2018 08:04:07 AEDT ]]> Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19533 95% of the identified indication bias. Slightly lower relapse incidence was found among patients treated with glatiramer acetate or subcutaneous interferon β-1a relative to intramuscular interferon β-1a and interferon β-1b (p≤0.001). No differences in 12-month confirmed progression of disability were observed. Conclusion: Small but statistically significant differences in relapse outcomes exist among the injectable immunomodulators. MSBase is sufficiently powered to identify these differences and reflects practice in tertiary MS centres. While the present study controlled indication, selection and attrition bias, centre-dependent variance in data quality was likely.]]> Sat 24 Mar 2018 08:02:06 AEDT ]]> Seasonal variation of relapse rate in multiple sclerosis is latitude dependent https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19821 Sat 24 Mar 2018 07:56:56 AEDT ]]> Risk of relapse phenotype recurrence in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20329 Sat 24 Mar 2018 07:55:11 AEDT ]]> The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28472 2 than ≤2. Two-point progression was uncommon for EDSS score of <2 and more common at EDSS score of 4. Conclusions: EDSS rank stability increases with disease duration, probably due to reduced relapses and less random variation in later disease. After 4 years duration, EDSS rank was highly predictive of EDSS rank 5 years later. Risk of progression by 10 years was highly dependent on EDSS score at 5 years duration. We confirm the utility of EDSS ranking to predict 5-year outcome in individuals 4 years after disease onset.]]> Sat 24 Mar 2018 07:39:35 AEDT ]]> Increasing age at disability milestones among MS patients in the MSBase Registry https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28467 Sat 24 Mar 2018 07:39:33 AEDT ]]> Sex as a determinant of relapse incidence and progressive course of multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28805 P < 10−12). However, the female-to-male ratio in patients with relapse-onset multiple sclerosis and zero relapses in any given year was double that of the patients with primary progressive multiple sclerosis. Patient age was a more important determinant of decline in relapse incidence than disease duration (P < 10−12). Females are predisposed to higher relapse activity than males. However, this difference does not explain the markedly lower female-to-male sex ratio in primary progressive multiple sclerosis. Decline in relapse activity over time is more closely related to patient age than disease duration.]]> Sat 24 Mar 2018 07:38:27 AEDT ]]> Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30101 Sat 24 Mar 2018 07:37:59 AEDT ]]> Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29942 -23). A reciprocal relationship was seen for ambient ultraviolet radiation (UVR), with a significantly increasing AAO for patients with MS per each quartile increment of ambient UVR (p=1.56×10-17). We found that the AAO of female patients was ~5 months earlier than male patients (p=0.002). AAO of progressive-onset patients with MS were ~9 years later than relapsing-onset patients (p=1.40×10-265). Conclusions: An earlier AAO in higher latitude regions was found in this worldwide European-descent cohort and correlated inversely with variation in latitudinal UVR. These results suggest that environmental factors which act at the population level may significantly influence disease severity characteristics in genetically susceptible populations.]]> Sat 24 Mar 2018 07:31:01 AEDT ]]> The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23959 Sat 24 Mar 2018 07:10:07 AEDT ]]> Determinants of therapeutic lag in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49695 Mon 29 May 2023 12:46:42 AEST ]]> Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37732 p = 0.001), brainstem onset (HR = 0.45, p = 0.009), azathioprine (HR = 0.46, p <0.001) and mycophenolate mofetil (HR = 0.09, p = 0.012) were associated with a reduced risk of relapse. A greater EDSS was associated with age (β = 0.45 (per decade), p<0.001) and disease duration (β = 0.07 per year, p <0.001). A slower increase in EDSS was associated with azathioprine (β = -0.48, p <0.001), mycophenolate mofetil (β = -0.69, p = 0.04) and rituximab (β = -0.35, p = 0.024). Interpretation: This study has demonstrated that azathioprine and mycophenolate mofetil reduce the risk of relapses and disability progression is modified by azathioprine, mycophenolate mofetil and rituximab. Age and disease duration were the only patient characteristics that modified the risk of relapse and disability in our cohort.]]> Mon 29 Mar 2021 13:09:59 AEDT ]]> Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48109 Mon 27 Feb 2023 15:22:15 AEDT ]]> Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36719 Mon 24 Aug 2020 10:45:35 AEST ]]> Predictors of treatment switching in the Big Multiple Sclerosis Data Network https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54767 Mon 11 Mar 2024 15:00:30 AEDT ]]> Defining secondary progressive multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25306 Mon 06 Mar 2023 17:55:37 AEDT ]]> Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41309 Mon 01 Aug 2022 12:30:36 AEST ]]> Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46553 Fri 25 Nov 2022 11:33:34 AEDT ]]> Contribution of different relapse phenotypes to disability in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34630 Fri 05 Apr 2019 11:37:25 AEDT ]]> Towards personalized therapy for multiple sclerosis: prediction of individual treatment response https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34026 80%) for relapse incidence during the first year and for disability outcomes, moderate for relapse incidence in Years 2–4 and for the change in the cumulative disease burden, and low for conversion to secondary progressive disease and treatment discontinuation. External validation showed similar results, demonstrating high external validity for disability and relapse outcomes, moderate external validity for cumulative disease burden and low external validity for conversion to secondary progressive disease and treatment discontinuation. We conclude that demographic, clinical and paraclinical information helps predict individual response to disease-modifying therapies at the time of their commencement.]]> Fri 01 Feb 2019 10:45:46 AEDT ]]>